Eiger BioPharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.03.18	Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
06.03.18	Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March (PR Newswire)
05.03.18	Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting (PR Newswire)
06.02.18	Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February (PR Newswire)
17.01.18	EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs? (RTTNews)
16.01.18	Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint (PR Newswire)
08.01.18	Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors (PR Newswire)
04.01.18	Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients (PR Newswire)
03.01.18	Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer (PR Newswire)
02.01.18	Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018 (PR Newswire)
01.12.17	John Hancock Premium Dividend Fund And Tax-Advantaged Dividend Income Fund Declare Monthly Distributions And Capital Gain Distributions (PR Newswire)
13.11.17	Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference (PR Newswire)
09.11.17	Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results (PR Newswire)
06.11.17	Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
23.10.17	Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus (HDV) Infection at the American Association for the Study of Liver Diseases (AASLD)... (PR Newswire)
17.10.17	HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL (RTTNews)
02.10.17	Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting (PR Newswire)
18.09.17	Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors (PR Newswire)
07.09.17	JazzHR Makes Inc. 5000 List for Second Consecutive Year and Wins SIIA CODiE Award (PR Newswire)
05.09.17	Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection (PR Newswire)
30.08.17	Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences (PR Newswire)
14.08.17	Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results (PR Newswire)
27.07.17	Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection (PR Newswire)
24.07.17	Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection (PR Newswire)
18.07.17	Gainers & Losers Of July 17: ACRX, QDEL, AKCA, SGMO, SUPN... (RTTNews)
30.06.17	Gainers & Losers Of June 29: OBSV, SBBP, EIGR, BIOS, PBMD... (RTTNews)
14.06.17	Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors (PR Newswire)
12.06.17	Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego (PR Newswire)
06.06.17	Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients (PR Newswire)
30.05.17	Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th (PR Newswire)
17.05.17	Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema (PR Newswire)
15.05.17	Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PR Newswire)
12.05.17	Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results (PR Newswire)
04.05.17	Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City (PR Newswire)
03.05.17	Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection (PR Newswire)
24.04.17	Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago (PR Newswire)
21.04.17	Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017 (PR Newswire)
18.04.17	Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia (PR Newswire)
23.03.17	Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results (PR Newswire)
06.03.17	Eiger BioPharmaceuticals to Present at the ROTH and Oppenheimer Investor Conferences in March 2017 (PR Newswire)
30.01.17	Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th (PR Newswire)
04.01.17	Eiger Completes $25 Million Debt Financing with Oxford Finance (PR Newswire)
03.01.17	Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH) (PR Newswire)
12.12.16	Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) (PR Newswire)
29.11.16	Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) (PR Newswire)
21.11.16	Eiger BioPharmaceuticals to Participate in Two Investor Conferences in November 2016 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.76	1.99 %	K V
CieFinRichemont	122.80	1.36 %	K V
Lonza Grp	532.20	1.06 %	K V
Logitech Intl	72.48	0.39 %	K V
Nestle	76.08	0.16 %	K V
Swisscom	505.00	-0.79 %	K V
Sika	229.30	-0.82 %	K V
ABB	49.41	-1.10 %	K V
Holcim	88.46	-1.47 %	K V
UBS Group	27.79	-1.98 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Eiger BioPharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten